Table 2.
Comparison of the incidence of cancer between the control and actinic keratosis groups.
| Control groups (N = 307,190) | Actinic keratosis (N = 61,438) | P-value | |||
|---|---|---|---|---|---|
| Event | % | Event | % | ||
| Number of subjects with any cancers | 15,755 | 5.13 | 4420 | 7.19 | < 0.01 |
| Skin cancer | 89 | 0.03 | 61 | 0.1 | < 0.01 |
| Oral cavity and pharyngeal cancer | 242 | 0.08 | 96 | 0.16 | < 0.01 |
| Lymphoma | 337 | 0.11 | 108 | 0.18 | < 0.01 |
| Leukemia | 252 | 0.08 | 68 | 0.11 | 0.03 |
| Prostate cancer† | 1466 | 0.48 | 398 | 0.65 | < 0.01 |
| Renal cancer | 351 | 0.11 | 91 | 0.15 | 0.03 |
| Multiple myeloma | 200 | 0.07 | 26 | 0.04 | 0.04 |
| Liver cancer | 1742 | 0.57 | 423 | 0.69 | < 0.01 |
| Thyroid cancer | 1070 | 0.35 | 259 | 0.42 | < 0.01 |
| Laryngeal cancer | 118 | 0.04 | 27 | 0.04 | 0.53 |
| Esophageal cancer | 215 | 0.07 | 49 | 0.08 | 0.41 |
| Gastric cancer | 2590 | 0.84 | 585 | 0.95 | < 0.01 |
| Colorectal cancer | 3279 | 1.07 | 674 | 1.1 | 0.52 |
| Pancreatic cancer | 1374 | 0.45 | 320 | 0.52 | 0.01 |
| Biliary cancer | 858 | 0.28 | 161 | 0.26 | 0.46 |
| Lung cancer | 2578 | 0.84 | 549 | 0.89 | 0.18 |
| Bladder cancer | 636 | 0.21 | 149 | 0.24 | 0.08 |
| Cancer of central nervous system | 274 | 0.09 | 71 | 0.12 | 0.05 |
| Breast cancer* | 880 | 0.29 | 190 | 0.31 | 0.34 |
| Uterine cervical cancer* | 251 | 0.08 | 51 | 0.08 | 0.92 |
| Uterine corpus cancer* | 155 | 0.05 | 37 | 0.06 | 0.33 |
| Ovarian cancer* | 283 | 0.09 | 61 | 0.1 | 0.60 |
| Testicular cancer† | 29 | 0.01 | 5 | 0.01 | 0.76 |
*Female malignancies were analyzed in 187,925 female controls and 37,585 female actinic keratosis patients.
†Male malignancies were analyzed in 119,265 male controls and 23,853 male actinic keratosis patients.